Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetacaine is a prescription topical anesthetic combination developed and marketed by Cetylite Industries. It contains three active small molecule ingredients: benzocaine (14%), butamben (2%), and tetracaine hydrochloride (2%). These agents work synergistically to produce rapid-onset anesthesia (within 30 seconds) by reversibly blocking voltage-gated sodium channels, thereby inhibiting nerve conduction. It is indicated for use on all accessible mucous membranes (except the eyes) to provide local anesthesia during dental and medical procedures, suppress the gag reflex, and facilitate endoscopic or surgical interventions in the respiratory and gastrointestinal tracts. The duration of anesthesia typically lasts 30 to 60 minutes when used as directed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetacaine.